Aimmune Therapeutics (AIMT) sees Significant Insider Buying

Monday, February 26, 2018 10:15 PM ET

Aimmune Therapeutics (AIMT) sees Significant Insider Buying

The number of insider buy/sell trades at Aimmune Therapeutics is above that of the 19 peer company average over the last 90-day period. The Proprietary & Advanced Pharmaceuticals peer group saw 18 buy/sell trades during this period for an average of 0.9 transactions per company. However, the number of shares traded per transaction by Aimmune Therapeutics insiders is lower than its peers. Within the peer group there were 582,473 shares purchased and 14,936 shares sold with company insiders acquiring 35,471 shares on average over this time period.

In determining significant insider buying and selling, trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data used to compose and write this story.

Today’s Insider Activity
* Eric Bjerkholt, Officer, bought 3,125 shares
* Kathryn E Falberg, Director, bought 30,000 shares
* Patrick G Enright, 10% Owner and Director, bought 15,593 shares
* Mark T Iwicki, Director, bought 9,375 shares
* Bakker Juliet Tammenoms, 10% Owner, bought 9,375 shares

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.